Abstract | AIM: MATERIALS AND METHODS: Seventy-eight hospitalized patients with an acute exacerbation of COPD were randomized into two groups: 1) 37 patients took nebulized budesonide 4 mg/day; 2) 41 patients received intravenous prednisolone. The symptoms of COPD, forced expiratory volume in one second (FEV1) and other spirometric indicators, peripheral blood oxygen saturation (SpO2), and adverse events were studied. The serum levels of the soluble adhesion molecules CD50 (sCD50) and CD54 (sCD54) and the lymphocyte activation molecules CD38 (sCD38) and CD25 (sCD25) were investigated by an enzyme immunoassay. RESULTS: CONCLUSION: Nebulized budesonide is an effective and safe alternative to SGCS in treating an exacerbation of COPD. Inhaled GCSs, unlike SGCSs, exhibit anti-inflammatory activity, but exert no immunosuppressive activity.
|
Authors | E V Makarova, G N Varvarina, N V Menkov, M Yu Czapaeva, E S Lazareva, Zh A Kazatskaya, V V Novikov, A V Karaulov |
Journal | Terapevticheskii arkhiv
(Ter Arkh)
Vol. 88
Issue 3
Pg. 24-31
( 2016)
ISSN: 0040-3660 [Print] Russia (Federation) |
PMID | 27030325
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Adrenal Cortex Hormones
- Antigens, CD
- Bronchodilator Agents
- Budesonide
- Prednisolone
|
Topics |
- Administration, Inhalation
- Adrenal Cortex Hormones
(administration & dosage, pharmacology)
- Adult
- Antigens, CD
(blood, drug effects)
- Bronchodilator Agents
(administration & dosage, pharmacology)
- Budesonide
(administration & dosage, pharmacology)
- Female
- Humans
- Male
- Middle Aged
- Nebulizers and Vaporizers
- Outcome Assessment, Health Care
- Prednisolone
(administration & dosage, pharmacology)
- Pulmonary Disease, Chronic Obstructive
(drug therapy, physiopathology)
|